CD4 and neoplasm: A combined antitumor treatment containing the aforementioned andecaliximab coupled with nivolumab/anti-PDL1 (an immune checkpoint inhibitor) in a syngeneic HER2-driven breast cancer (HC11-NeuT) tumor model drives intratumoral T-cell receptor diversity and promotes the antitumor response by increasing the protein level of Th1-type cytokines and infiltration of CD3+ T cells, including effector memory CD4 and CD8 positive T cells, into tumors [179].